Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Sun Kyung | - |
dc.contributor.author | Lee, Kyu Taek | - |
dc.contributor.author | Bae, Sang Byung | - |
dc.contributor.author | Lee, Sang-Cheol | - |
dc.date.accessioned | 2021-08-11T09:23:47Z | - |
dc.date.available | 2021-08-11T09:23:47Z | - |
dc.date.issued | 2019-11 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4120 | - |
dc.description.abstract | The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한내과학회 | - |
dc.title | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3904/kjim.2019.071 | - |
dc.identifier.scopusid | 2-s2.0-85074378544 | - |
dc.identifier.wosid | 000493981500003 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Internal Medicine, v.34, no.6, pp 1188 - 1196 | - |
dc.citation.title | The Korean Journal of Internal Medicine | - |
dc.citation.volume | 34 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1188 | - |
dc.citation.endPage | 1196 | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002518822 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | FLUOROURACIL PLUS LEUCOVORIN | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | RAS MUTATIONS | - |
dc.subject.keywordPlus | LIVER METASTASES | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | INFUSIONAL FLUOROURACIL | - |
dc.subject.keywordPlus | CETUXIMAB TREATMENT | - |
dc.subject.keywordPlus | ORAL CAPECITABINE | - |
dc.subject.keywordAuthor | Palliative | - |
dc.subject.keywordAuthor | Chemothreapy | - |
dc.subject.keywordAuthor | Metastatic colorectal cancer | - |
dc.subject.keywordAuthor | Survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.